Julie Rubinstein Sells 30,941 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $15.67, for a total transaction of $484,845.47. Following the completion of the sale, the chief operating officer owned 583,911 shares in the company, valued at approximately $9,149,885.37. This trade represents a 5.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Julie Rubinstein also recently made the following trade(s):

• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $16.00, for a total value of $495,056.00.

Adaptive Biotechnologies Stock Down 6.8%

Shares of Adaptive Biotechnologies stock opened at $14.85 on Friday. The business has a 50-day moving average price of $16.80 and a 200 day moving average price of $15.81. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.26 and a fifty-two week high of $20.76. The firm has a market cap of $2.29 billion, a P/E ratio of -37.12 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. During the same quarter last year, the firm earned ($0.23) EPS. The business’s revenue was up 51.0% on a year-over-year basis. As a group, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ADPT. BTIG Research lifted their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday. Morgan Stanley initiated coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 target price on the stock. Finally, TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of ADPT. AQR Capital Management LLC increased its holdings in shares of Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after purchasing an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP acquired a new stake in shares of Adaptive Biotechnologies during the first quarter worth approximately $93,000. Envestnet Asset Management Inc. purchased a new position in Adaptive Biotechnologies during the second quarter valued at approximately $467,000. Finally, Versor Investments LP purchased a new position in Adaptive Biotechnologies during the second quarter valued at approximately $367,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.